减毒四价登革热疫苗:上市后疫苗安全性与有效性评估的需求与挑战
自2015年12月起,首个登革热疫苗在多个亚洲和拉丁美洲国家获批用于预防全部四种登革病毒血清型所致疾病。该疫苗在临床试验中显示总体良好的安全性和有效性,但关键研究问题仍使某些人群的风险获益评估困难。本文总结公共卫生监测和针对性上市后研究的科学与方法学考量,以解决减毒登革热疫苗相关关键研究问题。
要点
- 疫苗在临床试验中显示总体良好的安全性和有效性,但关键研究问题仍使某些人群风险获益评估困难。
- 极罕见免疫接种后不良事件、疫苗诱导保护持久性和公共卫生项目中的有效性需上市后研究和国家监测系统数据。
- 登革热流行病学、发病机制和人群免疫复杂性及疫苗特性对现有监测系统评估构成挑战,尤其在中低收入国家。
核心结论
- 打算引入登革热疫苗的国家应评估其监测和评价疫苗有效性和安全性的能力,并酌情尽可能相应加强监测系统。
- 需要针对性研究,特别是更好地了解对血清阴性个体接种疫苗的影响。
研究设计与样本
- 本文为综述,总结公共卫生监测和针对性上市后研究的科学和方法学考量,以解决减毒登革热疫苗相关关键研究问题。
主要发现
- 目前获批疫苗在首次接种时登革血清状态和登革病毒血清型方面的有效性不同。
- 在一项试验中观察到,开始接种疫苗三年后,年幼接种儿童登革热住院风险增加。
- 目前尚不清楚上述现象是否仅限于较年轻年龄,还是也可能影响9岁及以上血清阴性个体,后者属于疫苗获批人群。
临床怎么用
- 打算引入登革热疫苗的国家应评估其监测和评价疫苗有效性和安全性的能力,并酌情尽可能相应加强监测系统。
- 需要针对性研究,特别是更好地了解对血清阴性个体接种疫苗的影响。
局限性
- 目前尚不清楚接种后三年观察到的年幼接种儿童登革热住院风险增加是否仅限于较年轻年龄,还是也可能影响9岁及以上血清阴性个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since December 2015, the first dengue vaccine has been licensed in several Asian and Latin American countries for protection against disease from all four dengue virus serotypes. While the vaccine demonstrated an overall good safety and efficacy profile in clinical trials, some key research questions remain which make risk-benefit-assessment for some populations difficult. As for any new vaccine, several questions, such as very rare adverse events following immunization, duration of vaccine-induced protection and effectiveness when used in public health programs, will be addressed by post-licensure studies and by data from national surveillance systems after the vaccine has been introduced. However, the complexity of dengue epidemiology, pathogenesis and population immunity, as well as some characteristics of the currently licensed vaccine, and potentially also future, live-attenuated dengue vaccines, poses a challenge for evaluation through existing monitoring systems, especially in low and middle-income countries. Most notable are the different efficacies of the currently licensed vaccine by dengue serostatus at time of first vaccination and by dengue virus serotype, as well as the increased risk of dengue hospitalization among young vaccinated children observed three years after the start of vaccination in one of the trials. Currently, it is unknown if the last phenomenon is restricted to younger ages or could affect also seronegative individuals aged 9years and older, who are included in the group for whom the vaccine has been licensed. In this paper, we summarize scientific and methodological considerations for public health surveillance and targeted post-licensure studies to address some key research questions related to live-attenuated dengue vaccines. Countries intending to introduce a dengue vaccine should assess their capacities to monitor and evaluate the vaccine's effectiveness and safety and, where appropriate and possible, enhance their surveillance systems accordingly. Targeted studies are needed, especially to better understand the effects of vaccinating seronegative individuals.
引用
- Wichmann O, Vannice K, Asturias EJ, et al. Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Vaccine. 2017. PMID: 28893477. doi:10.1016/j.vaccine.2017.08.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。